Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SYDNEY, Australia, July 17, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) would like to update shareholders on its current financial status subsequent to the closing of the...
-
SYDNEY, Australia, July 16, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced it will receive a second undisclosed significant...
-
SYDNEY, Australia, July 09, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” the “Company”) today announced that its collaboration partner, the Institute of Clinical Cancer...
-
SYDNEY, Australia, June 29, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced it has entered into a securities purchase agreement with...
-
SYDNEY, Australia, June 26, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD), has provided an update on the Company’s two active clinical trials in IMP321. Prima is pleased to...
-
LAG-3Ig (IMP321) Demonstrates Positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial
SYDNEY, Australia, June 04, 2017 (GLOBE NEWSWIRE) -- Breast cancer clinical trial demonstrates LAG-3Ig (IMP321) is safe and well toleratedData shows IMP321 in combination with chemotherapy leads to...
-
New Clinical Advisory Board comprises team of internationally renowned cliniciansProvides strategic advice for clinical development of lead drug candidate IMP321 in AIPAC metastatic breast cancer...
-
SYDNEY, Australia, May 17, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced that an abstract and poster have been accepted for...
-
SYDNEY, Australia, April 18, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced that approval has been granted for the third cohort of its...
-
SYDNEY, Australia, April 12, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”), is pleased to announce that it has received a A$492,144 cash rebate from...